Intratect (Human Normal Immunoglobulin)

Intratect, a pooled human immunoglobulin, is used to replace deficient antibodies and modulate immune activity in several immune‑related conditions.

• Primary immunodeficiency diseases: restores IgG levels to reduce infection risk.
• Secondary immunodeficiency: provides passive immunity when antibody production is compromised.
• Idiopathic thrombocytopenic purpura (ITP): raises platelet counts by modulating auto‑antibody activity.
• Kawasaki disease: reduces inflammation and coronary artery complications.
• Guillain‑Barré syndrome: shortens disease progression by attenuating autoimmune attack on peripheral nerves.

• Human normal immunoglobulin consists of pooled IgG antibodies derived from thousands of donors. After intravenous infusion, the IgG distributes throughout vascular and extravascular compartments, where it binds to pathogens, toxins and auto‑antibodies, neutralizing them. The Fc region engages immune regulatory receptors, inhibiting complement activation and modulating cytokine release, thereby providing passive immunity and immunomodulation.

Intratect may be associated with a range of adverse reactions following intravenous administration.

Common Side Effects

• Headache: mild to moderate headache during or after infusion.
• Fever: transient elevation in temperature.
• Nausea: mild gastrointestinal upset.
• Fatigue: general tiredness.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate treatment.
• Thromboembolic events: blood clots such as deep vein thrombosis.
• Renal dysfunction: acute kidney injury or reduced renal function.

Before administering Intratect, several precautions should be observed.

• Pre‑infusion assessment: evaluate patient’s IgG levels and infection history.
• Infusion rate: start slowly and monitor vital signs to reduce reaction risk.
• Cardiovascular status: monitor patients with heart disease for fluid overload.
• Renal function: assess kidney function before administration, especially in high‑risk patients.
• Concomitant immunosuppressants: adjust dosing and monitor for increased infection risk.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Intratect can interact with other medicines; awareness of major and moderate interactions helps ensure safety.

Major Interactions (Avoid)

• Live vaccines: concurrent use may reduce vaccine efficacy and increase risk.
• High‑dose aspirin or NSAIDs: may increase bleeding risk when combined with immunoglobulin‑induced platelet changes.
• Rituximab: may diminish the therapeutic effect of immunoglobulin.

Moderate Interactions (Monitor Closely)

• Anticoagulants (e.g., warfarin): monitor coagulation parameters.
• Diuretics: watch for fluid balance changes during infusion.
• ACE inhibitors: observe for hypotension during rapid infusion.